LSV Asset Management Sells 259,370 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

LSV Asset Management cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,028,498 shares of the biopharmaceutical company's stock after selling 259,370 shares during the period. Gilead Sciences accounts for 1.1% of LSV Asset Management's portfolio, making the stock its 12th largest holding. LSV Asset Management owned 0.40% of Gilead Sciences worth $464,482,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of GILD. XTX Topco Ltd bought a new position in Gilead Sciences in the 3rd quarter valued at about $581,000. LRI Investments LLC grew its position in shares of Gilead Sciences by 289.9% in the third quarter. LRI Investments LLC now owns 811 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 603 shares during the last quarter. Executive Wealth Management LLC bought a new position in shares of Gilead Sciences during the third quarter worth approximately $222,000. M&T Bank Corp boosted its stake in Gilead Sciences by 3.2% in the 3rd quarter. M&T Bank Corp now owns 192,952 shares of the biopharmaceutical company's stock valued at $16,177,000 after purchasing an additional 5,943 shares during the period. Finally, Coldstream Capital Management Inc. grew its holdings in Gilead Sciences by 9.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 22,882 shares of the biopharmaceutical company's stock valued at $1,932,000 after buying an additional 2,043 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Remove Ads

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 302,785 shares of company stock valued at $30,503,250. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on GILD shares. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $105.12.

Gilead Sciences Trading Up 2.9 %

Shares of NASDAQ GILD traded up $3.04 during midday trading on Monday, reaching $106.67. The stock had a trading volume of 2,532,004 shares, compared to its average volume of 7,481,789. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company's 50 day moving average price is $108.34 and its 200 day moving average price is $96.89. The firm has a market cap of $132.82 billion, a price-to-earnings ratio of 288.30, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.